lung cancer

We will be reporting directly from the annual congress of the European Society for Medical Oncology (ESMO) in Munich, Germany, from October 19 to October 23.

Analysen richtungsweisender Studien am ELCC 2019 sowie aktuelle Forschungsresultate könnten künftig neue und gezieltere Therapieansätze ermöglichen.

The 1% cut-off value for PD-L1 might become a better predictive marker than the other cut-off values, and even minimal expression of PD-L1 protein may have a negative prognostic significance.

Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage III lung cancer, according to late-breaking results from the phase III PACIFIC trial presented today at the ESMO 2017 Congress in Madrid